Webcast Alert: Lippert/Heilshorn Life Sciences Virtual Conference (Aradigm)
Posted on: Monday, 17 March 2008, 12:00 CDT
Aradigm (ARDM) announces the following Webcast:
What: Lippert/Heilshorn Life Sciences Virtual Conference
When: March 18, 2008 @ 11:30 PM Eastern
Where: http://www.investorcalendar.com/ClientPage.asp?ID=127170
How: Live over the Internet -- Simply log on to the web at the address above.
Contact: Ben Carmichael, 212-838-3777, bcarmichael@lhai.com
If you are unable to participate during the live webcast, the call will be available for replay at http://www.investorcalendar.com/ClientPage.asp?ID=127170 or http://www.investorcalendar.com/
Aradigm Corporation is a specialty pharmaceutical company focused on the development and commercialization of a portfolio of drugs delivered by proprietary inhalation technologies. These drugs are intended to be prescribed by pulmonologists for the treatment or prevention of severe respiratory diseases. Inhalation delivery offers a number of advantages over other routes of administration, including more rapid onset of action, less drug required to achieve the desired therapeutic effect and fewer side effects as the body has less drug exposure. The Company has five programs in active development; disease targets include cystic fibrosis, bronchiectasis, pulmonary arterial hypertension (PAH), smoking, asthma and chronic obstructive pulmonary disease (COPD). Aradigm was founded in 1991 and is based in Hayward, Calif.
Source: Business Wire
Related Articles
- Aradigm and APT Move Asthma Treatment into Phase II
- Aradigm and APT Pharmaceuticals Initiate Phase 2 Clinical Program of Novel Treatment for Asthma
- Aradigm Seeks Orphan Drug Status for Cystic Fibrosis Candidate
- Aradigm and United Therapeutics Sign Development and Commercialization Agreement Targeting Pulmonary Hypertension
- Aradigm and APT Pharmaceuticals Announce Progression of AERx HCQ Program Into Phase 2 Clinical Trials
- Aradigm Advances Development of Intraject Sumatriptan With New Clinical Trial Data
- Aradigm Expands Financial and Strategic Strength on Closing of Restructured Licensing Agreement With Novo Nordisk
- Aradigm Announces $12.5M Private Placement Financing
- Aradigm Announces Results From Clinical Study of Intraject Needle-Free System With Sumatriptan
User Comments (0)

RSS Feeds